Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin 2, Dublin, Ireland.
BMC Ophthalmol. 2012 Sep 2;12:46. doi: 10.1186/1471-2415-12-46.
Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs.
Based on the evidence of large-scale clinical studies investigating the systemic administration of fenofibrate, this ligand for peroxisome proliferator-activated receptor-α is potentially a good candidate for intraocular delivery. Here, we describe the mechanisms by which it might be acting to improve diabetic retinopathy, its relative safety and we speculate on how it could be developed for intraocular delivery.
In this paper, we provide a rationale for the further investigation of peroxisome proliferator-activated receptor-α agonists as intraocular agents for the treatment of diabetic retinopathy.
针对过氧化物酶体增殖物激活受体的系统治疗方法已被发现对糖尿病性视网膜病变的治疗有益。在本文中，我们提供了将这些治疗剂用作眼内药物的基本原理。此外，我们介绍了过氧化物酶体增殖物激活受体，并描述了它们对药物的反应功能。
基于大规模临床试验研究全身给予非诺贝特（过氧化物酶体增殖物激活受体-α的配体）的证据，这种药物可能是眼内递送的一个很好的候选药物。在这里，我们描述了它可能作用于改善糖尿病性视网膜病变的机制，它的相对安全性，并推测了如何为眼内递送而开发它。
在本文中，我们为进一步研究过氧化物酶体增殖物激活受体-α激动剂作为治疗糖尿病性视网膜病变的眼内药物提供了依据。
